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Objective. To investigate the safety (risk) and eﬃcacy (benefit) of Echinacea purpurea extract in the prevention of common cold
episodes in a large population over a 4-month period. Methods. 755 healthy subjects were allocated to receive either an alcohol
extract from freshly harvested E. purpurea (95% herba and 5% root) or placebo. Participants were required to record adverse
events and to rate cold-related issues in a diary throughout the investigation period. Nasal secretions were sampled at acute colds
and screened for viruses. Results. A total of 293 adverse events occurred with Echinacea and 306 with placebo treatment. Nine and
10% of participants experienced adverse events, which were at least possibly related to the study drug (adverse drug reactions).
Thus, the safety of Echinacea was noninferior to placebo. Echinacea reduced the total number of cold episodes, cumulated episode
days within the group, and pain-killer medicated episodes. Echinacea inhibited virally confirmed colds and especially prevented
enveloped virus infections (P < 0.05). Echinacea showed maximal eﬀects on recurrent infections, and preventive eﬀects increased
with therapy compliance and adherence to the protocol. Conclusions. Compliant prophylactic intake of E. purpurea over a 4-month
period appeared to provide a positive risk to benefit ratio.
1. Introduction
The common cold is recognized as the most frequent disease
in Western civilization and the number one cause of primary
health care consultations [1, 2]. The costs of illness associated
with noninfluenza infections are estimated at 40 billion
USD, including direct and indirect costs. With the additional
costs of illness caused by influenza, upper respiratory tract
infections present a serious burden to humanity and to the
economy [3, 4].
Colds comprise a syndrome of symptoms, typically
with nasal complaints, cough, sore throat, and sometimes
constitutional complaints, like headache, malaise, and fever
[5]. The symptoms are typically self-limiting, and they
represent a reaction to infection by Rhino-, Corona-, Adeno-,
Respiratory Syncytial and (Para-) influenza virus [6].
The development of eﬀective cold preventives is ham-
pered by themultiplicity of viruses and the complex interplay
between host and virus [7, 8]. For decades, intense research
has focused on applications of broad-spectrum antivirals
like interferons (α, β, or γ), capsid binding proteins, or
soluble receptors directed against rhinoviral infection and/or
replication. Some therapies showed eﬃcacy in clinically
induced infections but failed to significantly prevent colds
in larger field studies that included multiple types of
respiratory viruses. Nasal applications of interferons showed
good preventative eﬃcacy but were typically accompanied by
adverse reactions like nasal bleeding [9].
Vaccination presents an eﬀective method for managing
seasonal influenza and respiratory, syncytial virus (RSV) in
children. However, the eﬃcacy of vaccination depends on
the immunological fitness of the recipient and primarily in
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older individuals or those with chronic heart disease only
insuﬃcient immunity can be built up, resulting in a reduced
immunity in this vulnerable population [10, 11].
Another method for preventing cold infections is to
modulate the immune system [12]. In this context, Echinacea
plays an important therapeutic role [13]. For several decades,
Echinacea has been used to prevent colds and the flu [14].
Despite its worldwide acceptance, only limited data are avail-
able on its prophylactic eﬃcacy. Long-term clinical trials that
studied spontaneous colds, conducted by Schoeneberger,
Schmidt and Schenk, Cohen et al., and Melchart et al.,
reported mixed results [15–18]. Three studies on artifi-
cially induced rhinovirus infections showed a trend toward
preventing symptomatic cold episodes by Echinacea [19–
21]. Generally, the prophylactic benefits reached significance
when data were pooled in a meta-analysis, because single
studies tended to have small sample sizes and undefined or
low statistical power [22].
On the other hand, a good safety profile is mandatory
for therapies that are designed to be taken over several
months [23]. Considering the mild-to-moderate nature of
the common cold, a potential preventive therapy by itself
must induce only a minimal safety risk to produce a positive
risk benefit ratio. In the predominant absence of side eﬀects a
suﬃciently important diﬀerence of 20–32% is expected from
cold treatments like vitamins and herbal extracts [24, 25].
The present study aimed to examine safety parameters
of E. purpurea during long-term treatment. The study was
designed to also investigate the eﬃcacy profile with prede-
fined, primary variables of eﬃcacy and with an appropriate
sample size based on power calculations. Overall, this study
represented the largest clinical trial ever performed to test the
safety and eﬃcacy of Echinacea extract, and it was the first
study to employ virus screening techniques.
2. Materials and Methods
2.1. Study Design. This study was a randomized, double-
blind, parallel, placebo-controlled clinical trial conducted
at the Common Cold Center in Cardiﬀ University (United
Kingdom). The study was conducted according to the
declaration of Helsinki (2000), the international conference
on harmonization, good clinical practice regulations, the
association of the British Pharmaceutical Industry, and the
human tissue authority. The trial received ethical approval
from the local ethics committee by 28th July 2009 and, finally,
from the medicines and healthcare products regulatory
agency (MHRA) on the 2nd July 2009. The study was
registered under the Eudra-CT number, 2009-012297-12.
From October to November 2009, healthy participants were
included in the study and were randomly allocated to receive
either E. purpurea extract or placebo. At the inclusion visit,
every participant received medication to cover 1 month of
treatment and a diary for daily recordings of adverse reac-
tions (“did you have any unusual or unexpected symptoms
today?”), the presence and severity of cold-related symptoms
and the use of any concurrent medication. Participants
returned each month to the study center, and they returned
any unused medication and the completed diaries. After
checking compliance and the completion of the returned
diary, a new treatment and diary were issued for another
month. After the acceptance of an amendment to the study
protocol, we also handed out three kits for self-collection
of nasal secretions during acute cold episodes. Each kit
contained a mid-turbinate nasal swab, suitable for self-
collection, a vial that contained universal transport medium
for storage at room temperature (COPAN, Brescia, Italy),
and a bag for safe transport of the samples (DaklaPack,
Oberhausen, Germany).
2.2. Treatment. The Echinacea product was the commercially
available Echinaforce drops produced by A. Vogel Bioforce
AG, Switzerland. Echinaforce was prepared by alcoholic
(57.3% m/m) extraction from freshly harvested E. purpurea
with a combination of 95% herba (DER = 1 : 12) and 5%
roots (DER = 1 : 11). The sample wasmicrobiologically tested
and proven to be free of endotoxins. The batch used in
this study (027643) was standardized to contain 5mg/100 g
of dodecatetraenoic acid isobutylamide, based on high-
performance liquid chromatography measurements. Placebo
drops were similar in shape, color, consistency, odor, flavor,
and they contained the same amount of alcohol. The liquids
were aliquoted into amber bottles and closed with a screw
cap attached to an integrated, calibrated syringe for accurate
dosing (0.9mL/dose). Primary and secondary packaging was
identical for the verum and placebo.
2.3. Dosing. The therapy regimen was in accordance with
the recommendation by the manufacturer. Participants
swallowed 3 × 0.9mL per day for illness prevention. This
corresponded to 2400 mg of extract per day. During acute
stages of colds, the participants were instructed to increase
the dose to 5 × 0.9mL per day; this totaled a daily dose of
4000mg of extract. Each single dose was diluted in water
and retained in the mouth for 10 s. This application method
was expected to provide maximum local antiviral eﬀects.
Compliance was assessed at the monthly visits by weighing
the returned bottles. Adherence to the recommended dosing
was calculated based on the total prophylactic and acute
dosing recorded in the diary. Overall, the method of
administration reflected the traditional use of E. purpurea,
and it provided accurate Echinaforce dosing.
2.4. Study Participants and Randomization. Participants were
recruited via advertisements around the university campus.
At first contact, respondents received an info-leaflet describ-
ing the trial. The study inclusion criteria were adults (≥18
years old) of good physical condition, that experienced ≥2
colds per year. The exclusion criteria were ineﬀective con-
traception; participation in another study; women that were
pregnant or breast feeding; current cold infection; currently
taking antimicrobial or antiviral medication; alcohol or drug
abuse; psychiatric disorders; epilepsy; attempted suicide;
planned surgical intervention; serious chronic disease that
could influence absorption, metabolism, or elimination of
the medication; known AIDS or other autoimmune diseases;
diabetes type 1; corticosteroid-treated asthma; medicinally
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treated atopy or allergy; a known allergy to plants of the com-
posite family (Asteraceae). Volunteers with clinically relevant
laboratory abnormalities were dropped out after inclusion.
All participants provided signed, informed consent.
A total of 755 subjects were included. Subjects were
randomly allocated to receive treatment or placebo. The
randomization code was prepared in block-sizes of 6 with
the “RANCODE Professional 3.6” program. Each participant
received treatment based on his/her identification number,
which was allocated according to the time point of inclusion.
Drugs were personally dispensed by the investigator or
personnel authorized by the investigator. The randomization
procedure was prepared by a statistician. The original ran-
domization code was retained by the statistician in a sealed
envelope, and one copy was conveyed to the investigator.
Only in a case of emergency the investigator was permitted
to open the envelope that contained the identification of a
treatment.
The blinding of the study treatment was found to
be adequate, when pretested in 79 test persons. In both
treatment groups, nearly half of the participants believed
that they were given the Echinaforce preparation (17 of 38
subjects (45%) with placebo and 19 of 41 subjects (46%)
with verum). A total of 15 recipients of placebo (39%) and
17 (42%) with verum stated that they did not know which
preparation they were given.
2.5. Sample Size Calculation. With at least 300 evaluable
subjects in each group, assuming a 0.2 proportion of
individuals with adverse drug reactions (ADRs) within each
group, the upper limit of the observed one-sided 97.5%
confidence interval of the diﬀerence between the placebo
proportion, πP, and the Echinaforce proportion, πE, was
expected to be less than 0.1 with 86% power. Assuming a
20% drop-out rate, where 20% of participants would not
follow the study per protocol for the entire 4 months of
treatment, we estimated that 750 subjects would be required
for inclusion into the study. With 700 cumulated episode
days in the Echinaforce group, an anticipated prophylactic
eﬀect of 25%, resulting in 875 episode days for the placebo
group, the study had suﬃcient statistical power to show
prophylactic benefits with P < 0.05.
2.6. Clinical Outcome Measurements and Statistical Analysis.
Over the entire study period, all participants retained a diary
to record AEs by answering the question “Did you have any
unusual or unexpected symptoms today?” Moreover, at the
monthly study visits, participants were interviewed about
acute or experienced events by the study physician. The AE
analysis included all AEs with a date/time of onset on or after
the start date of the study treatment. The analysis excluded
AEs with a date/time of onset that occurred before the start
date or when information on the date/time of onset was
missing. All AEs were coded with the lowest level terms from
the latest installed version of the MedDRA Dictionary (V.
13.1).
For AEs described by a physician(s), the lowest level
term was chosen that best matched the physician’s actual
description. These lowest level terms were translated into
preferred terms (PTs) and classified into a system organ class
(SOC) employing the latest installed version of the MedDRA
Dictionary (V. 13.1). Primary analysis was performed on the
basis of the per protocol population.
At inclusion and exclusion visits, participants provided
blood samples. These were processed to determine clinical
chemistry, hematology parameters, and diﬀerential blood
cell counts. Clinically relevant abnormalities that deviated
from the normal range were flagged by the laboratory. The
final safety criterion was the assessment, by participants and
physicians, of therapy tolerability.
Causal relationship between recorded AEs and the study
medication was rated by the physician as either “not
related,” “unlikely,” “possible,” “probable/likely,” “certain,”
“not assessable/unclassifiable,” “unknown,” or “not appli-
cable.” AEs that were at least “possibly” related to the
medication were considered adverse drug reactions (ADRs);
these were included in the primary analysis of the per
protocol collective (PP). With this respect, the proportion
of patients with any ADRs was compared between groups
to determine the non-inferiority of the treatment. To prove
safety, there should be less than a 10% (non-inferiority
limit) diﬀerence between the proportions of patients with
ADRs in the Echinaforce and placebo groups. The alternative
hypothesis (HA) of interest was to show non-inferiority by
determining that the proportion of patients with ADRs in the
Echinaforce group (πE) would be lower than the proportion
of patients with ADRs in the placebo group (πP) plus delta
(i.e., HA: πE < πP + δ). The alternative hypothesis was
accepted when the upper 95% confidence limit (two-sided)
of the diﬀerence in proportions between Echinaforce and
placebo was lower than delta. For this study, delta (δ) was
0.1, corresponding to 10%. The occurrence of AEs was a
secondary safety variable and was deduced from the safety
collective.
The second question the participant answered in the
diary, “Do you believe you have a cold today?” was answered
yes or no. During acute colds, the symptoms “headache,”
“chilliness,” “sneezing,” “nasal obstruction,” “nasal dis-
charge,” “sore throat,” “cough,” and “malaise” were rated on
a 4-point Likert scale with 0 or no entry = absence, 1 = mild,
2 =moderate, and 3 = severe symptoms. In addition, the par-
ticipant indicated in the diary the daily intake of concomitant
medication and/or therapy. This matrix was based on the
work by Jackson and colleagues, who described the clinical
features and symptoms of a virally induced common cold
[1]. Their definition is currently accepted as the most valid
method for diﬀerentiating a cold from isolated symptoms
(like hay fever or allergies) that do not develop into the
clinical picture of a cold. Thus, a cold episode was defined
as a minimal total symptom score of 14 (summed over 6
consecutive days), and the participants believed they had a
cold and/or reported rhinorrhea that lasted for≥3 days. A set
of three predefined prophylactic variables were analyzed in a
confirmatory manner: (1) the total number of cold episodes,
(2) cumulative episode days, and (3) comedicated cold
episodes. The three parameters were analyzed individually
with a chi-square test to determine whether the ratio of
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cumulated events (i.e., cold episodes) in the treatment
groups corresponded to the ratio of the underlying group
samples. The primary eﬃcacy analysis focused on episodes
with durations <9 days that occurred in the intention to treat
(ITT) population. The null-hypothesis was rejected when the
chi-square statistic was >3.84, resulting in a P value <0.05.
Likewise, the incidence of recurrent infections in the whole
group was compared to the underlying group samples with
a chi-square statistic analysis. The primary analysis of the
preventive eﬃcacy was in agreement with earlier work by
Schmidt and Schenk or Tiralongo [16, 26].
Nasal secretions were collected during acute stages of
colds. Samples were inserted into a transport vial and stored
at the study site at −70◦C. At the end of the clinical trial, the
samples were analyzed for the presence of respiratory viruses
(Provincial Health Services Authorities, PHSA; BC Center
for Disease Control, Vancouver Canada). Briefly, RNA was
isolated from the nasal secretions using MagMax Express
96 Nucleic Acid Extractor (Applied BioSystems, Foster City
CA) and screened with a Respiratory Virus Panel. The FAST
Multiplex panel (Roche Diagnostics, Basel, Switzerland)
could detect the following viruses (Virus Type/Subtype):
Influenza A H1/H3, Influenza B, Respiratory Syncytial Virus,
Coronavirus 229E/OC43/NL63/HKU1, Parainfluenza virus
1–4, human Metapneumovirus, Entero-rhinovirus, Aden-
ovirus, and human Bocavirus. Frequency ratios of every
virus and ofmembranous virus infections between treatment
groups were compared to the underlying group sizes using a
chi-square test.
All statistical analyses were performed with the SAS
system (Version 9.2) and Testimate 6.4 (IDV, Datenanalyse
und Versuchsplanung, Gauting/Mu¨nchen).
3. Results
A total of 755 study subjects were screened and allocated into
one of the treatment groups between October and November
2009. Of these, 673 subjects completed the study; the last
patient visit was conducted in late April 2010. Eighty-two
(10.9%) subjects discontinued the trial prematurely; of these,
38 were out of contact after randomization, 16 withdrew
consent, 3 terminated the study due to technical reasons, 3
terminated due to intolerable AEs or deterioration of the
participant’s health, and 22 withdrew for no documented
reason. A complete flow diagram of participant disposition
is shown in Figure 1.
3.1. Demographic Data and Other Baseline Characteristics.
The two groups were comparable with regard of age, gender,
body weight, height, and body mass index (BMI). There
was no noticeable diﬀerence between groups in anamnestic
variables, including blood pressure or heart rate. The only
variable that was significantly diﬀerent between groups was
the susceptibility to colds, measured as the number of colds
experienced in the past. Participants in the placebo group
were significantly less susceptible to infections than those
in the Echinacea group (P < 0.05, Fisher’s exact test) (see
Table 1).
Table 1: Demographic and anamnestic data from participants in









Age (years) (SD) 23.6 (7.8) 23.2 (7.2) P > 0.05 (n.s)∗
Body weight (kg) (SD) 67.7 (13.1) 69.5 (13.1) P > 0.05 (n.s)∗
Body height (cm) (SD) 167.5 (9.0) 168.1 (8.9) P > 0.05 (n.s)∗
Body mass index (SD) 24.1 (4.0) 24.5 (3.9) P = 0.05 (n.s)∗
Gender
Female N (%) 244 (68.7) 227 (62.7) P > 0.05 (n.s)∗∗
Male N (%) 111 (31.3) 135 (37.3)
Colds in the past; N
(SD)
3.0 (1.18) 2.8 (1.06) P < 0.05∗
3.2. Analysis of Safety Variables. A total of 25 subjects in the
Echinaforce group (9.0%) and 30 subjects in the placebo
group (10.0%) experienced 27 and 30 ADRs, respectively.
The percentage diﬀerence was −0.97%, with an upper limit
of the one-sided 97.5% confidence interval of 3.6%, which is
less than 10%. Consequently, Echinaforce was demonstrated
to be noninferior to placebo in the incidence of ADRs as per
protocol population.
A total of 293 AEs were reported by 177 subjects treated
with Echinaforce and 306 AEs were reported by 172 subjects
in the placebo group (safety collective). Four AEs in the
Echinaforce group and 3 in the placebo group led to
discontinuation of treatment (Table 2). No severe AE was
observed with Echinaforce. One severe AE (glandular fever)
occurred with placebo, and this required hospitalization.
Overall, no significant diﬀerence could be identified in
the occurrence of AEs between groups, whether related or
unrelated to the study drug (Fisher’s exact test). This did
not change when considering the total numbers, the system
organ class, or the preferred terms (data not shown).
In the hematological or biochemical measures no sig-
nificant or clinically relevant changes from before to after
Echinaforce treatment and in comparison to placebo were
detected. No abnormalities were found after the 4-month
exposure to Echinaforce. Previously reported safety concerns
like induction of allergic reactions, leucopenia, or autoim-
mune diseases were not observed under Echinacea treatment
[27].
About 64% of participants in the Echinaforce group
and 71% in the placebo group assessed the tolerability of
the medicine to be “good” or “very good.” There was no
significant diﬀerence between groups.
3.3. Analysis of Prophylactic Eﬃcacy. Eﬃcacy was assessed
concurrent with the safety variables during the long-term
treatment with Echinaforce. A priori case definitions were
made for sample size (calculation), statistical methodology,
and measurements of probability or clinical end point.
The placebo group had a total of 188 cold episodes,
with a collective duration of 850 episode days; in com-
parison, the Echinaforce group had 149 episodes with a








N = 24 N = 14No contact after
randomization
N = 355 N = 362At least one contact after
inclusion
State of health 1
Intolerable adverse events2
Technical reasons 2
Withdrawal of consent 10
No reason documented 15
Premature discontinuation
Technical reasons 1
Withdrawal of consent 6
No reason documented 7
N = 325 Study termination N = 348
Figure 1: Flow diagram of participant disposition.
Table 2: Overview of adverse events (AEs) and adverse drug reactions (ADRs) that occurred during the study period in the safety collective.
Echinaforce (N = 355) Placebo (N = 362) Total (N = 717)
Number (%) of participants with
(i) adverse events 177 (49.9) 172 (47.5) 349 (48.7)
(ii) drug-related AEs1 35 (9.9) 35 (9.7) 70 (9.8)
(iii) serious AEs 0 (0.0) 1 (0.3) 1 (0.1)
(iv) AEs leading to treatment discontinuation 3 (0.8) 2 (0.6) 5 (0.7)
Number of events2
(i) adverse events 293 306 599
(ii) drug-related AEs1 39 36 75
(iii) serious adverse events 0 1 1
(iv) AEs leading to treatment discontinuation 4 3 7
1AEs that were causally related to the study medication with ratings of certain, probable/likely, or possible.
2AEs were based on the Preferred Terms (PTs), each PT counted only once per participant.
collective duration of 672 episode days (ITT population).
The diﬀerence of cumulated events (episodes and episode
days) between the treatment groups each of 26% reached
statistical significance for episode days (P < 0.05, chi-square
test). A total of 65 recurring infections were observed in 28
participants with Echinacea and 100 episodes in 43 subjects
under placebo treatment. The diﬀerence of 59% reached
statistical significance as well (P < 0.05, chi-square test).
Concurrent medication was a significant factor in the
present study. In the Echinacea and placebo groups, 58
and 88 episodes, respectively, were treated with aspirin,
paracetamol, or ibuprofen. Thus, significantly more (+52%)
cold episodes in the placebo group were additionally treated
with pain medication (P < 0.05, chi-square test). The
median of painkiller medicated cold episodes was 0 in the
Echinaforce group and 1 in the placebo group.
A total of 201 nasal secretion samples were collected in
the study; 86 in the Echinacea group and 115 in the placebo
group, a diﬀerence with borderline significance (P = 0.0663,
chi-square test). In 128 samples, the presence of a respi-
ratory virus was confirmed. Throughout the whole study
period, 54 viral infections were detected in the Echinaforce
treated group and 74 were detected in the placebo group.
Intriguingly, the strongest eﬀect was seen with membranous
viruses, like Corona-, Influenza-, Parainfluenza-, Respiratory
Syncytial- and Metapneumovirus with 24 and 47 detected
infections in the two groups (P < 0.05, chi-square test). In
total, 14 recurring viral infections occurred under Echinacea,
i.c. to 34 under placebo.
In long-term studies (here, 4 months), compliance
represents a sensible factor. Therefore, we specifically exam-
ined a population that took ≥100% of the recommended
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study medication for the entire study period. Eighty-eight
compliant subjects in the Echinacea group reported 36
infections and 155 episode days; in comparison, in the
placebo group, 58 episodes were reported with 268 episode
days. This represented a 53% diﬀerence in the number of
episode days. Despite the low denominators, this diﬀerence
was highly statistically significant (P < 0.0001, chi-square
test). Similar eﬀects were observed in a group that was
compliant in documentation (i.e., they reported at least
one AE and/or one cold symptom in the diary during 4
months). However, these analyses were of explorative nature
and served to substantiate the preventive eﬀects of Echinacea
in a compliant group. Moreover, the compliant group was
less aﬀected by confounders.
4. Discussion
Prevention of mild-to-moderate diseases, like the common
cold, requires therapies with satisfactory safety and eﬃcacy
profiles. The common cold is particularly in need of
preventive treatments, due to its high frequency and high
associated costs of illness [3]. It is assumed that the typical
adult spends up to 2 years over a lifetime with cold symptoms
[28]. Despite its prevalence and substantial research eﬀort in
the past, no specific preventive treatment has been developed
to date that has a tolerable safety profile for use over the long
term [7].
In the present study, safety and eﬃcacy variables were
analyzed over a collective total of 11,472 weeks or 2,868
months of prophylaxis from 717 subjects. We used a
highly sensitive method to detect AEs, and we included the
physician’s experience to assess causality (ADRs). In addi-
tion, extensive laboratory tests were conducted to examine
hematologic and metabolic parameters.
The overall safety profile of Echinaforce was very good,
based on the total AEs, the ADRs, and the laboratory mea-
surements, within the treatment group and in comparison
with placebo. In addition, the global tolerability assessments
by the physicians and participants were quite positive. The
fact that more than 75% mentioned that they would take
the medicine again indicated that a 4-month treatment with
Echinaforce was well accepted. Although the present data
did not indicate any safety concern with Echinacea in a large
population and over an extended period of time, we cannot
fully exclude the possibility of rare and very rare adverse
events with our data.
The study also assessed cold episodes using a highly
accepted method developed by Jackson et al. [1]. The
study was designed and large enough to show preventive
eﬃcacy with suﬃcient power. We employed a predefined and
validated case definition, sample size calculations, statistical
methodology, and measurements of probability according
to a confirmatory approach [29]. Statistically significant
diﬀerences between Echinacea and placebo were found for
cumulative cold episode days and for comedicated episodes.
Overall, we had expected about 1000 cold episodes, but we
observed only 337 cold episodes. Although the treatment
eﬀect on the number of cold episodes was the same as for
cumulated episode days, the statistical power was insuﬃcient
to detect a significant diﬀerence between groups for this
parameter.
A diﬀerence of 26% between groups in an open-field,
long-term prevention study was comparable with a previous
study on the eﬀects of nasally administered interferons, and
this diﬀerence can be considered clinically relevant [13, 24,
25]. In the present study, two covariates confounded the
reported outcome significantly. First, participants in the
Echinacea group had a higher susceptibility to colds than
those in the placebo group. Second, participants in the Echi-
nacea group reported less frequent use of classical pain med-
ications and also of chlorphenamine, a codeine/cocodamol
or pseudoephedrine. Adjusting for these covariates would
most likely have resulted in an even higher eﬀect, closer to
the results reported from viral analyses and subgroups which
shared similar anamnestic conditions. Previous studies have
described the problems associated with assessing cold infec-
tions purely on subjective symptomatic grounds [7, 30].
Therefore, we aimed to substantiate our data with virus anal-
yses in nasal secretions. Viruses were successfully detected via
reverse transcriptase polymerase chain reaction (RT-PCR) in
about 60% of samples. It was diﬃcult to draw conclusions
about specific viruses, due to the low overall number of
samples. Therefore, we aimed to confirm our previous in
vitro data, which showed that Echinacea had strong antiviral
eﬀects against membranous viruses [31, 32]. Indeed, upon
pooling the incidences of Influenza, Parainfluenza, RSV,
Metapneumovirus, or Coronaviruses, we found 47 total
infections in the placebo group and only 24 infections in the
Echinacea group (P = 0.0114, chi-square test). The individ-
ual reduction on infection depended of the respective virus
type. These results were fully consistent with previous studies
by Pleschka et al. that demonstrated similar antiviral eﬀects
with the same preparation used in the present study [31, 32].
5. Conclusion
The present work described the largest clinical trial to date
that tested the safety and eﬃcacy of Echinacea and investi-
gated its risk/benefit in a long-term treatment. Prophylactic
treatment with Echinaforce over 4 months appeared to be
beneficial for many reasons. First, Echinaforce showed an
advantageous safety profile; it did not induce any health
risk above that reported with the placebo treatment. Second,
prolonged treatment with Echinaforce was associated with
significant therapeutic benefits.
Overall, the risk/benefit results from this clinical study
suggested that long-term treatment with E. purpurea over 4
months can be recommended.
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